Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Upadacitinib retreatment was safe and effective in patients who had treatment withdrawn.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: July 27, 2020

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Related Content

Expert slides from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Released: September 22, 2020

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Expert-authored commentary on investigational selective JAK inhibitors in atopic dermatitis treatment from Clinical Care Options (CCO)

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO

Released: August 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue